We are live on ! Find out more
Stempoint Capital

Stempoint Capital Portfolio holdings

AUM $560M Turnover 64.34%
1-Year Est. Return 146.87%
This Fund
S&P 500
This Quarter Est. Return
+54.5%
1 Year Est. Return
+146.87%
3 Year Est. Return
+725.67%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$583M
AUM Growth
+$84.1M
Cap. Flow
-$28.8M
Cap. Flow %
-4.93%
Top 10 Hldgs %
45.64%
Holding
119
New
32
Increased
28
Reduced
17
Closed
42
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.4 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.4 years

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$63.7M
2
DNLI icon
Denali Therapeutics
DNLI
+$22.2M
3
IMVT icon
Immunovant
IMVT
+$21.1M
4
QURE icon
uniQure
QURE
+$18.5M
5
WVE icon
Wave Life Sciences
WVE
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Miscellaneous 0.09%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ABVX icon
1
Abivax
ABVX
$6.41B
$52.8M 9.06%
391,783
+225,510
+136% +$24.6M
2025 Q2
2 quarters
SRRK icon
2
Scholar Rock
SRRK
$5.87B
$39.1M 6.7%
886,893
+160,689
+22% +$6.03M
2024 Q4
4 quarters
CNTA
3
DELISTED
Centessa Pharmaceuticals
CNTA
$28.9M 4.95%
1,154,114
+498,729
+76% +$12.6M
2024 Q3
5 quarters
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$785M
$28.1M 4.83%
1,339,379
-26,826
-2% -$468K
2023 Q4
8 quarters
GPCR icon
5
Structure Therapeutics
GPCR
$1.15B
$24.4M 4.19%
351,073
+221,738
+171% +$9.05M
2025 Q3
1 quarter
ACLX icon
6
DELISTED
Arcellx
ACLX
$21.7M 3.72%
332,860
+321,484
+2,826% +$25.6M
2025 Q1
3 quarters
ROIV icon
7
Roivant Sciences
ROIV
$28B
$21M 3.6%
966,698
-3,230,489
-77% -$63.7M
2023 Q4
8 quarters
TERN icon
8
DELISTED
Terns Pharmaceuticals
TERN
$17.3M 2.97%
429,198
+339,581
+379% +$7.85M
2025 Q3
1 quarter
TWST icon
9
Twist Bioscience
TWST
$7.04B
$16.4M 2.82%
+518,355
New +$16.2M
2025 Q4
0 quarters
IMVT icon
10
Immunovant
IMVT
$6.57B
$16.4M 2.81%
644,959
-944,621
-59% -$21.1M
2023 Q4
8 quarters
DYN icon
11
Dyne Therapeutics
DYN
$2.9B
$16.3M 2.8%
835,200
+360,588
+76% +$6.83M
2025 Q3
1 quarter
XENE icon
12
Xenon Pharmaceuticals
XENE
$3.64B
$15.6M 2.68%
348,605
+156,310
+81% +$6.56M
2025 Q3
1 quarter
SRZN icon
13
Surrozen
SRZN
$542M
$12.7M 2.17%
619,766
-93,697
-13% -$1.52M
2024 Q2
6 quarters
CELC icon
14
Celcuity
CELC
$2.61B
$11.8M 2.02%
118,333
-18,377
-13% -$1.51M
2025 Q3
1 quarter
MLYS icon
15
Mineralys Therapeutics
MLYS
$1.21B
$10.5M 1.8%
290,049
+131,937
+83% +$5.29M
2025 Q2
2 quarters
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$8.81B
$10.3M 1.77%
17,736
+9,529
+116% +$4.87M
2025 Q1
3 quarters
ADPT icon
17
Adaptive Biotechnologies
ADPT
$4.52B
$9.9M 1.69%
+606,825
New +$9.9M
2025 Q4
0 quarters
PALI icon
18
Palisade Bio
PALI
$151M
$9.9M 1.69%
+4,192,375
New +$8.06M
2025 Q4
0 quarters
CYTK icon
19
Cytokinetics
CYTK
$7.07B
$9.34M 1.6%
+146,978
New +$9.14M
2025 Q4
0 quarters
EWTX icon
20
Edgewise Therapeutics
EWTX
$4.37B
$8.96M 1.54%
+360,876
New +$7.24M
2025 Q4
0 quarters
DRUG icon
21
Bright Minds Biosciences
DRUG
$201M
$7.6M 1.3%
+97,340
New +$6.51M
2025 Q4
0 quarters
NKTR icon
22
Nektar Therapeutics
NKTR
$1.03B
$7.54M 1.29%
178,274
+125,073
+235% +$7M
2025 Q3
1 quarter
JNJ icon
23
Johnson & Johnson
JNJ
$651B
$7.24M 1.24%
+35,000
New +$6.92M
2025 Q4
0 quarters
DNLI icon
24
Denali Therapeutics
DNLI
$2.96B
$6.92M 1.19%
419,058
-1,315,601
-76% -$22.2M
2024 Q2
6 quarters
AMLX icon
25
Amylyx Pharmaceuticals
AMLX
$3.35B
$6.83M 1.17%
565,140
+288,256
+104% +$3.92M
2025 Q3
1 quarter

Similar funds

Stempoint Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Stempoint Capital held 119 positions worth $583M, up 17% from $499M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Stempoint Capital withdrew a net $28.8M in Q4 2025, closing 42 positions and reducing 17 holdings. Its most notable exit was Wave Life Sciences, an estimated $15.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Stempoint Capital opened a new position in Twist Bioscience worth $16.4M.

  • Stempoint Capital's largest Q4 2025 buy was Twist Bioscience: 518,355 shares worth $16.4M.
  • Stempoint Capital added most to Arcellx in Q4 2025, an estimated $25.6M increase.
  • Stempoint Capital's biggest Q4 2025 reduction was Roivant Sciences, cutting an estimated $63.7M.
  • Stempoint Capital fully exited Wave Life Sciences in Q4 2025, selling an estimated $15.4M.
  • Stempoint Capital's ten largest holdings make up 46% of its $583M portfolio in Q4 2025.
  • Stempoint Capital opened 32 new positions and closed 42 in Q4 2025.
  • Stempoint Capital's portfolio value rose 17% quarter-over-quarter to $583M.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.